mva-mers-s_df1
Vaccineexperimental
Clinical trial activity
1 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2020 (NCT04119440)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Middle East respiratory syndrome-related coronavirusImmunity, active
Middle East respiratory syndrome-related coronavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04119440 | Phase 1 | May 31, 2020 | Coalition for Epidemic Preparedness Innovations, CR2O, CTC Bio, Inc., Erasmus University Rotterdam, German Center for Infection Research, IDT Biologika, University of Hamburg |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Coalition for Epidemic Preparedness Innovations | Academic/Hospital | 1 | 0 | 1 | 2020 |
| CR2O | For profit | 1 | 0 | 1 | 2020 |
| CTC Bio, Inc. | For profit | 1 | 0 | 1 | 2020 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2020 |
| German Center for Infection Research | Academic/Hospital | 1 | 0 | 1 | 2020 |
| IDT Biologika | For profit | 1 | 0 | 1 | 2020 |
| University of Hamburg | Academic/Hospital | 1 | 1 | 1 | 2020 |
7 organizations
Page 1 / 1